Liquidia Corporation

Liquidia is a biopharmaceutical company developing and commercializing therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its work combines proprietary formulations, innovative drug-delivery methods, and PRINT particle-engineering technology to improve therapeutic performance. The company also collaborates with pharmaceutical partners and focuses on addressing unmet needs for patients and healthcare providers worldwide.